Apyx Medical Corporation APYX
2.93 USD 0.00 (+0.00%)
Nov 9, 2026, 2:25 PM EST
2.92 Day range 3.05
2.25 52-week range 5.08
- YTD
- -16.29%
- 1 year
- -24.29%
News
seekingalpha.com Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
zacks.com Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago.
benzinga.com Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.410M Est Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.410 million estimate.
benzinga.com Apyx Medical Q3 EPS $(0.04) Beats $(0.09) Estimate, Sales $14.030M Beat $13.290M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 20 percent increase over losses of $(0.05)…
globenewswire.com Apyx Medical Corporation Reports Third Quarter 2026 Financial Results Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
benzinga.com Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09)…- benzinga.com Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
benzinga.com This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy rating with $55 PT.- benzinga.com HC Wainwright & Co. Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Yi Chen initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $7.
benzinga.com Apyx Medical Appoints Stavros Vizirgianakis Executive Chairman, Effective June 11 https://www.sec.gov/ix?doc=/Archives/edgar/data/719135/000149315226029081/form8-k.htm
benzinga.com Apyx Medical Publishes New Clinical Data In Aesthetic Surgery Journal Open Forum Highlighting Approach To Improving Cellulite And Skin Laxity In this study, 22 patients received a single treatment session combining these modalities to address both the structural and surface level causes of cellulite and skin laxity. Results showed…- benzinga.com Apyx Medical Announces Publication Of A New Retrospective Investigator-Initiated Study In Plastic And Reconstructive Surgery - Global Open The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).The results demonstrate that adding Renuvion to liposuction resulted in…
- benzinga.com Apyx Medical Raises FY2026 Sales Guidance from $57.500M-$58.500M to $59.000M-$60.000M vs $57.988M Est Apyx Medical (NASDAQ:APYX) raises FY2026 sales outlook from $57.500 million-$58.500 million to $59.000 million-$60.000 million vs $57.988 million estimate.
benzinga.com Apyx Medical Q1 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.490M Beat $10.868M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 50 percent increase over losses of $(0.10) per…- benzinga.com Craig-Hallum Maintains Buy on Apyx Medical, Raises Price Target to $6 Craig-Hallum analyst Matthew Hewitt maintains Apyx Medical (NASDAQ:APYX) with a Buy and raises the price target from $5 to $6.
benzinga.com This JM Smucker Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Wall Street analysts upgraded Uniqure NV, Apyx Medical Inc, J M Smucker Co, and VTEX with raised price targets. See analyst ratings page.
benzinga.com Earnings Scheduled For March 10, 2026 
benzinga.com Earnings Breakdown: Apyx Medical Q4 - benzinga.com Apyx Medical Sees FY2026 Sales $57.500M-$58.500M vs $55.480M Est Apyx Medical (NASDAQ:APYX) sees FY2026 sales of $57.500 million-$58.500 million vs $55.480 million analyst estimate.
- benzinga.com Apyx Medical Q4 EPS $(0.03) Beats $(0.06) Estimate, Sales $19.164M Beat $18.160M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 46.43 percent. This is a 75 percent increase over losses of $(0.12)…
benzinga.com A Preview Of Apyx Medical's Earnings 
benzinga.com Roth Capital Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $6 Roth Capital analyst Kyle Bauser initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $6.- benzinga.com Apyx Medical Announces Approval, Commercial Roll Out Of Apyx One Console, Single-Use Handpieces In South Korea Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced…
benzinga.com Apyx Medical Reveals Proposed Public Offering of Common Stock; No Size Disclosed Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced…- benzinga.com Citizens Upgrades Apyx Medical to Market Outperform, Announces $8 Price Target Citizens analyst David Turkaly upgrades Apyx Medical (NASDAQ:APYX) from Market Perform to Market Outperform and announces $8 price target.
- benzinga.com Apyx Medical Raises FY2025 Sales Guidance from $50.000M-$52.000M to $50.500M-$52.500M vs $50.001M Est Apyx Medical (NASDAQ:APYX) raises FY2025 sales outlook from $50.000 million-$52.000 million to $50.500 million-$52.500 million vs $50.001 million estimate.
- benzinga.com Apyx Medical Q3 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.877M Beat $12.002M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50.98 percent. This is a 64.29 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Apyx Medical Submits FDA 510(k) For Device Label Expansion Of AYON Body Contouring System Initiated Nationwide Commercial Launch of AYON in SeptemberThe Company is Hosting a Virtual Key Opinion Leader Event to Discuss the Commercial Launch of AYON on October 14, 2
benzinga.com Earnings Scheduled For August 7, 2025 - benzinga.com Apyx Medical Launches Renuvion In China Strong clinical interest and early procedures completedEntered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Apyx Medical Affirms FY2025 Sales Guidance of $47.60M-$49.00M vs $48.03M Est Apyx Medical (NASDAQ:APYX) affirms FY2025 sales outlook from $47.60 million-$49.00 million to $47.60 million-$49.00 million vs $48.03 million estimate.
- benzinga.com Apyx Medical Q1 EPS $(0.10) Beats $(0.12) Estimate, Sales $9.43M Beat $9.39M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 54.55 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Apyx Medical Q4 2024 GAAP EPS $(0.12) Beats $(0.15) Estimate, Sales $14.22M Beat $13.39M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 57.14 percent increase over losses of $(0.28)…
- benzinga.com Earnings Scheduled For March 13, 2025
- benzinga.com Apyx Medical Announces Q4 2024 Revenue Between $14.1M-$14.3M, A 3%-4% Decrease YOY; Advanced Energy Revenue Flat At $12.0M-$12.2M; OEM Revenue Down 17% To $2.1M; FY24 Revenue Between $48.0M-$48.2M, An 8% Decrease YOY; Advanced Energy Down 11% To $38.5M-$38.7M; OEM Up 6% To $9.5M. Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary…
- benzinga.com Apyx Medical Corp Submits 510(k) Premarket Notification To The U.S. FDA ForTthe AYON Body Contouring System Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Crude Oil Moves Lower; Accenture Shares Tumble After Q2 Results U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.77% to 39,814.95 while the NASDAQ rose 0.25% to 16,410.54. The…
- benzinga.com Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Gold Gains 1%; Micron Posts Upbeat Results U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.84% to 39,844.27 while the NASDAQ rose 0.61% to 16,469.28. The…
- benzinga.com Earnings Scheduled For March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.